JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

Home・Akcijų sąrašas・Vaxart Inc

Vaxart Inc

Uždarymo kaina

0.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	605K -15M
Pardavimai	19M 40M
Pelno marža	-37.72
Darbuotojai	105
EBITDA	155K -12M

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.4M 81M
Ankstesnė atidarymo kaina	0.32
Ankstesnė uždarymo kaina	0.32

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

0.4007 / 0.4252 Palaikymas ir pasipriešinimas

Vaxart Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-23 23:51; UTC

Rinkos pokalbiai

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025-10-23 23:37; UTC

Rinkos pokalbiai

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025-10-23 22:58; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-10-23 22:57; UTC

Rinkos pokalbiai

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -2-

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025-10-23 22:17; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025-10-23 21:41; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025-10-23 21:05; UTC

Uždarbis

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025-10-23 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-23 20:35; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025-10-23 20:28; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025-10-23 20:15; UTC

Rinkos pokalbiai

Uždarbis

Global Commodities Roundup: Market Talk

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Adj EPS $1.71

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Sales $5.52B

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q EPS $1.67

2025-10-23 20:09; UTC

Uždarbis

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025-10-23 20:07; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2025-10-23 20:07; UTC

Rinkos pokalbiai

Uždarbis

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025-10-23 20:07; UTC

Uždarbis

Blackstone Looks to IPOs for Investment Exits -- Update

2025-10-23 20:05; UTC

Uždarbis

Intel 3Q Gross Margin 38.2% >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025-10-23 20:04; UTC

Uždarbis

Intel: 4Q Guidance Excludes Altera >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Sees 4Q Adj EPS 8c >INTC

Akcijų palyginimas

Kainos pokytis

Vaxart Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Vaxart Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.4007 / 0.4252Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.